Naltrexone in the treatment of alcohol addiction Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2025
DOI: https://doi.org/10.24292/01.MF.0125.09
Keywords:
alcoholism, naltrexone, dual diagnosis, combination treatment

Main Article Content

Michał Danek
1. Oddział Leczenia Uzależnień, Szpital Uniwersytecki nr 1 w Bydgoszczy. 2. Katedra Psychiatrii, Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu

Abstract

According to the World Health Organization, alcohol is the third most important risk factor for the health of the population, and more than 200 types of illness and injury are associated with its consumption. In Poland, alcohol abuse is estimated at 3-4 million people, including about 900,000 with symptoms of dependence. The recommendations of the Polish Psychiatric Association list a number of drugs supporting the treatment of alcohol addiction - one of them is naltrexone. Naltrexone is an effective and at the same time safe drug supporting the treatment of alcohol dependence. Numerous studies cited in this study indicate the effectiveness of naltrexone in blocking the effect of positive reinforcement of alcohol consumption, as well as reducing its hunger and promoting abstinence.

Article Details

How to Cite
Danek, M. (2025). Naltrexone in the treatment of alcohol addiction. Medycyna Faktow (J EBM), 18(1(66), 61-66. https://doi.org/10.24292/01.MF.0125.09
Issue
Vol 18 No 1(66) (2025)
Section
Articles

Copyright by Medical Education. All rights reserved.

References

1. Krajowe Centrum Przeciwdziałania Uzależnieniom (KCPU). Raport "Uzależnienia w Polsce". 2023.
2. PARPA. Wzory konsumpcji alkoholu w Polsce. Raport z badań kwestionariuszowych. 2020.
3. Vetulani J. Alkoholizm i neurobiologia farmakoterapii alkoholizmu. Kraków 2013.
4. Ziółkowski M, Rybakowski J. Znaczenie naltreksonu w leczeniu uzależnienia alkoholowego. Farmakoterapia w psychiatrii i neurologii. 1999; 3: 10-7.
5. Bieńkowski P, Wojnar M, Mierzejewski P et al. Long-term pharmacotherapy aimed at maintaining abstinence or reducing alcohol intake in alcohol-dependent individuals. Guidelines from the Section of Pharmacotherapy of Polish Society for Research on Addictions (PTBU) and the Section of Psychopharmacology of Polish Psychiatric Association (PTP) - 2019 update. Farmakoterapia w Psychiatrii i Neurologii. 2019; 35(2): 95-110.
6. Charakterystyka produktu leczniczego Naltex z dnia 07.12.2018 r.
7. Bieńkowski P. Zastosowanie naltreksonu w terapii uzależnienia od alkoholu - aspekty farmakologiczne. Psych Pol. 2013; XLVII(1): 117-26.
8. Stahl SM. Podstawy psychofarmakologii Stahla. Poradnik lekarza praktyka. Tom 3. Via Medica, Gdańsk 2021.
9. Pettinati H, O'Brien C, Rabinowitz A et al. The status of naltrexone in the treatment of alcohol dependence specific effects on heavy drinking. J Clin Psychopharmacol. 2006; 26(6): 610-25.
10. McPheeters M, O'Connor EA, Riley S et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023; 330(17): 1653-65.
11. Jonas DE, Amick HR, Feltner C et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014; 311(18): 1889-900.
12. Klimkiewicz A, Klimkiewicz J, Jakubczyk A et al. Współwystępowanie uzależnienia od alkoholu z innymi zaburzeniami psychicznymi. Część II. Patogeneza i leczenie. Psychiatr Pol. 2015; 49(2): 277-94.
13. Pettinati HM, Oslin DW, Kampman KM et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010; 167(6): 668-75.
14. Roos CR, Bold KW, Witkiewitz K et al. Reward drinking and naltrexone treatment response among young adult heavy drinkers. Addiction. 2021; 116(9): 2360-71.
15. Klimkiewicz A, Klimkiewicz J, Jakubczyk A et al. Współwystępowanie uzależnienia od alkoholu z innymi zaburzeniami psychicznymi. Część I. Epidemiologia podwójnego rozpoznania. Psychiatr Pol. 2015; 49(2): 265-75.